Elsevier

Atherosclerosis

Volume 125, Issue 1, 23 August 1996, Pages 91-101
Atherosclerosis

Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study

https://doi.org/10.1016/0021-9150(96)05865-0Get rights and content

Abstract

Maintenance dialysis patients experience an exceedingly high incidence of arteriosclerotic cardiovascular disease (CVD) events that are poorly predicted by traditional CVD risk factor indices. We evaluated the prevalence of three non-traditional CVD risk factors, i.e. hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) (Lp(a)) excess, and combined hyperhomocysteinemia, hyperfibrinogenemia, and Lp(a) excess, in maintenance dialysis patients. Fasting total plasma homocysteine (Hcy), fibrinogen, Lp(a), glucose, and total and HDL cholesterol levels, and traditional CVD risk factor (i.e. glucose tolerance, smoking, hypertension, dyslipidemia) prevalences were assessed in 71 dialysis patients and 71 age, sex, and race matched Framingham Study controls free of clinical renal disease, with normal serum creatinine (≤ 1.5 mg/dl). Mean plasma Hcy (23.7 vs. 9.9 μM, P = 0.0001), fibrinogen (457 vs. 309 mg/dl, P = 0.0001), and Lp(a) (30 vs. 17 mg/dl, P = 0.0070) levels were substantially increased in the dialysis patients. Matched odds ratios (with 95% confidence intervals), dialysis patients/controls, for hyperhomocysteinemia, hyperfibrinogenemia, and Lp(a) excess, alone or combined, were markedly greater in the dialysis patients, with no evidence of confounding by the traditional CVD risk factors: hyperhomocysteinemia, 105.0 (29.9–368.9); hyperfibrinogenemia, 16.6 (6.6–42.0); Lp(a) excess, 3.5 (1.5–8.4); all three combined 35.0 (5.7–199.8). Given in vitro evidence that Hcy, Lp(a), and fibrinogen interact to promote atherothrombosis, combined hyperhomocysteinemia, hyperfibrinogenemia, and Lp(a) excess may contribute to the high incidence of vascular disease sequelae experienced by dialysis patients, which is inadequately explained by traditional CVD risk factors. Controlled, prospective studies of well-characterized maintenance dialysis cohorts are urgently required to substantiate this hypothesis.

References (80)

  • AG Bostom et al.

    Net uptake of plasma homocysteine by the rat kidney in vivo

    Atherosclerosis

    (1995)
  • A Araki et al.

    Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection

    J Chromatogr

    (1987)
  • RT Wall et al.

    Homocystine-induced endothelial injury in vitro: a model for the study of vascular injury

    Thromb Res

    (1980)
  • JW Heinecke et al.

    The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells

    J Biol Chem

    (1987)
  • NS Cook et al.

    Fibrinogen as a major risk factor in cardiovascular disease

    Trends Pharmacol Sci

    (1990)
  • MA Mansoor et al.

    Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria

    Metabolism

    (1993)
  • AG Bostom et al.

    Folate status is the major determinant of fasting total plasma homocysteine in maintenance dialysis patients

    Atherosclerosis

    (1996)
  • AG Bostom et al.

    High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients

    Kidney Int

    (1996)
  • AG Bostom et al.

    Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients

    Atherosclerosis

    (1996)
  • Excerpts From The United States Renal Data System, United States Renal Data System 1995 Annual Report

    Am J Kidney Dis

    (1995)
  • DN Churchill

    Comparative morbidity among hemodialysis and continuous ambulatory peritoneal dialysis patients

    Kidney Int

    (1993)
  • G Wu

    Cardiovascular deaths among CAPD patients

    Perit Dial Bull

    (1993)
  • PS Parfrey et al.

    Long term cardiac morbidity and mortality during dialysis therapy

    Adv Nephrol

    (1994)
  • MJ Stampfer et al.

    A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians

    J Am Med Assoc

    (1992)
  • J Selhub et al.

    Association between plasma homocysteine concentrations and extracranial carotid artery stenosis

    N Engl J Med

    (1995)
  • E Arnesen et al.

    Serum total homocysteine and coronary heart disease

    Int J Epidemiol

    (1995)
  • L Wilhelmsen et al.

    Fibrinogen as a risk factor for stroke and myocardial infarction

    N Engl J Med

    (1984)
  • MC Stone et al.

    Plasma fibrinogen — a major coronary risk factor

    J R Coll Gen Pract

    (1985)
  • WB Kannel et al.

    Fibrinogen and risk of cardiovascular disease: the Framingham Study

    J Am Med Assoc

    (1987)
  • A Rosengren et al.

    Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men

    Br Med J

    (1990)
  • EJ Schaefer et al.

    Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial

    J Am Med Assoc

    (1994)
  • P Cremer et al.

    Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)

    Eur J Clin Invest

    (1994)
  • AG Bostom et al.

    A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study

    Circulation

    (1994)
  • PC Harpel et al.

    Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential link between thrombosis, atherogenesis, and sulfhydryl compound metabolism

  • DEL Wilcken et al.

    Accumulation of sulphur-containing amino acids including cysteine-homocysteine mixed disulfide in patients on maintenance haemodialysis

    Clin Sci

    (1980)
  • SS Kang et al.

    Plasma protein-bound homocyst(e)ine in patients requiring chronic hemodialysis

    Clin Sci

    (1983)
  • P Chauveau et al.

    Hyperhomocyst(e)inemia, a risk factor for atherosclerosis in chronic uremic patients

    Kidney Int

    (1993)
  • B Hultberg et al.

    Plasma homocysteine in renal failure

    Clin Nephrol

    (1993)
  • SS Kim et al.

    Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients

    Adv Perit Dial

    (1994)
  • J Bachmann et al.

    Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients

    J Am Soc Nephrol

    (1995)
  • Cited by (111)

    • Vision Impairment in CKD Patients: Epidemiology, Mechanisms, Differential Diagnoses, and Prevention

      2019, American Journal of Kidney Diseases
      Citation Excerpt :

      Second, it has been suggested that the renin-angiotensin system has a role in the pathogenesis of glaucoma through its effect on the production and drainage of aqueous humor.55 Third, CKD accelerates atherosclerosis,56,57 and atherosclerosis is known to be related to primary open angle glaucoma. Fourth, the progression of CKD enhances the generation of oxygen free radicals such as reactive oxygen species,58 for which accumulation has been proposed to be relevant in the pathogenesis of glaucoma.50,59

    • Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort

      2008, Kidney International
      Citation Excerpt :

      We found that HCY had a modest impact on the association between CKD stages 3–5 and CAC. Although levels of HCY are elevated among pre-dialysis CKD vs non-CKD patients,23,24 less is known regarding the CVD risk associated with hyperhomocysteinemia in such subjects. Five previous studies examining the relationship between CKD and CAC did not include HCY as a covariate.12-16

    View all citing articles on Scopus
    View full text